Abuse-Deterrent Formulations

Dr. Mark Garofoli discusses a positive stride in advancing patient care and making efforts to ensure that lives within the national opioid crisis are saved and/or improved. One of those positive strides involves the FDA approval of abuse deterrent formulation (ADF) opioid medications, with the aim of preventing the transition from the misuse and/or abuse of prescription opioid medications to illicit drugs. How do these formulations work one might ask?